Meta Information
ID:sacubitril-valsartan
Name:Sacubitril/Valsartan
Schema Version:1.5
Alternate Names
- Entresto
Active Compound
sacubitril/valsartan
Intervention Type
therapeutic_agent
Delivery
Route:
oral
Scope:
- systemic
Regulatory Status
- us:rx_drug
- eu:rx_drug
Indication
Focus:
disease_treatment
Description:
Treatment of chronic heart failure with reduced ejection fraction (HFrEF) to reduce the risk of cardiovascular death and hospitalization.
Typical Protocol
- Typically initiated at 24/26 mg or 49/51 mg twice daily.
- Dose is doubled every 2-4 weeks to a target maintenance dose of 97/103 mg twice daily as tolerated.
Expected Cost Mean
Low Cost:
550
High Cost:
750
Cost Type:
monthly
Description:
Branded prescription medication cost; often covered by insurance with co-pay.
Summary
Sacubitril/Valsartan is a combination drug that treats heart failure by providing a dual mechanism of action. Valsartan, an angiotensin II receptor blocker (ARB), blocks the harmful effects of the renin-angiotensin-aldosterone system. Sacubitril is a neprilysin inhibitor, which increases levels of beneficial natriuretic peptides that protect the cardiovascular system, leading to vasodilation and reduced cardiac stress.
Purpose
Treats heart failure by relaxing blood vessels and reducing cardiac strain.
Card Summary
A dual-action prescription drug for heart failure that reduces cardiovascular strain and improves outcomes.
Drug Class
arni
Drugs In Class
Empty Array
Impact
Score:
9
Justification:
Foundational, first-line therapy for heart failure, significantly reducing mortality and hospitalization.
Evidence
Grade:
A
Score:
9.5
Justification:
Supported by large, high-quality randomized controlled trials (e.g., PARADIGM-HF).
Safety
Score:
5.5
Justification:
Requires medical supervision; common side effects include hypotension, hyperkalemia, and renal issues.
Flags
- Risk of hypotension (low blood pressure), especially when starting or increasing the dose.
- Can cause hyperkalemia (high potassium levels), requiring regular blood monitoring.
- May cause kidney function to worsen.
- Contraindicated in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy.
- Must not be co-administered with ACE inhibitors due to increased risk of angioedema.
- Fetal toxicity warning; should not be used during pregnancy.
Verdict
A foundational, life-saving medication for treating specific types of heart failure.
Created
2026-04-30T01:27:06.130316Z
Ai Model
Gemini 2.5 Pro (High)
Non Healthspan
True